Prostate Cancer | Specialty

The prostate cancer condition center is a comprehensive resource for clinical news and expert insights on prostate cancer. Read more at OncLive.

177Lu rhPSMA-10.1 Injection Generates Favorable Radiation Dosimetry Data in mCRPC

March 13th 2025

177Lu rhPSMA-10.1 injection led to proportionally higher absorbed radiation doses in tumors vs healthy tissues in patients with mCRPC.

Ongoing Research to Watch in Prostate Cancer in 2025 and Beyond

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.

Key Prostate Cancer Updates to Emerge From ASCO GU 2025

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.

Findings From a Real-World Analysis of ARPIs in Nonmetastatic CRPC

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.

Outcomes by Disease Volume: A Subgroup Analysis of the ARANOTE Trial in mHSPC

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.

Data From an Age-Related Subgroup Analysis of the ARASENS Trial in mHSPC

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.

The Evolution of Treatment in Metastatic Hormone-Sensitive Prostate Cancer

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.

Norway Grants Marketing Authorization to Illuccix PSMA-PET Imaging Agent in Prostate Cancer

March 5th 2025

NOMA has approved the PET imaging agent for the identification of PSMA-positive lesions in patients with prostate cancer.

FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

March 4th 2025

The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.

Analyses Show Effects of Treatment, Patient Location on HRQOL in Bladder and Prostate Cancer

March 1st 2025

HRQOL results were evaluated in rural patients with bladder cancer and prostate cancer following ADT treatment and postoperative radiotherapy.

Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management

February 24th 2025

Pedro Barata, MD, discusses the expansion of radioligand therapies and the identification of novel targets beyond PSMA in prostate cancer.

Darolutamide Provides Clinical Benefits vs Other AR Inhibitors in Black and White Patients With nmCRPC

February 24th 2025

Darolutamide generated lower treatment discontinuation rates and longer MFS vs enzalutamide or apalutamide in both Black and White patients with nmCRPC.

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Darolutamide With ADT/Docetaxel Shows Reduced Risk of Death in mHSPC Irrespective of Age

February 23rd 2025

Darolutamide plus ADT and docetaxel demonstrated efficacy benefits in men with mHSPC regardless of whether they were younger or older than 75 years of age.

Real-World Analysis Reveals Gaps in HRR Testing and PARP Inhibitor Treatment in mCRPC

February 22nd 2025

Most patients with mCRPC included in a real-world study did not undergo HRR testing at the time of diagnosis.

Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC

February 21st 2025

Pivotal phase 3 trials are ongoing following data from a phase 1 study showing that adding mevrometostat to enzalutamide was safe and efficacious.

67Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PSMA+ mCRPC

February 20th 2025

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

Dr Oh on the Development of Targeted Therapies in Prostate Cancer

February 17th 2025

William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management

February 17th 2025

Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.

OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer

February 17th 2025

Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.